 |
| Obesity, Diabetes & Vascular Disease - Apollo Protein a Global Hit |
Apollo's hcx proteins | Apollo’s supplies of human cell expressed Adiponectin (Adiponectin hcx™) are proving to be a worldwide best seller, with stocks running out within weeks of release, and further production runs already booked solid.
The international interest isn’t surprising given adiponectin is a hormone that has been shown to be linked to obesity, diabetes and vascular disease.
This gives it strong commercial potential, both as a therapeutic and as a research tool, according to Apollo’s Head of Sales and Marketing for the protein business, Leanne Daly.
"There is enormous interest in this hormone because of the diseases it is involved in – and there is even greater interest in Apollo’s Adiponectin, not only because it is expressed in human cells, but it also has a number of other features that make it superior to everything else that is available," she said. "We have also set up a collaborative research venture with scientists at Queensland University."
"The success of our Adiponectin means that we are on the right track in producing and marketing human cell expressed proteins – there is clearly a huge market for our products."
International pharmaceutical companies and research institutions are buying Apollo’s recently released tag-free Adiponectin hcx with its unique set of characteristics: it has greater biological activity than other forms of adiponectin on the market; it contains the high molecular weight form which is believed to be the most active form of adiponectin; and it is expressed in human cells, making it ideal for the development of therapies for treating human diseases.
Adiponectin is a cytokine produced and secreted into the bloodstream by fat cells (adipocytes). It controls the metabolism of lipids and glucose, influences how the body responds to insulin and has anti-inflammatory effects on the cells lining the walls of blood vessels.
Low levels are associated with obesity, insulin resistance, diabetes, and increased cardiovascular risk. Researchers have shown that adiponectin reduces blood glucose and lipid levels, as well as atherosclerosis (hardening of the arteries) in animal models.
Apollo’s adiponectin is a potent activator of an enzyme called AMPK, which is known to have a role in fatty acid oxidation and glucose update. Impaired fatty acid oxidation and glucose uptake are hallmarks of insulin resistance and type 2 diabetes.
|
|
|
| click to subscribe |
|
 |
| www.apollolifesciences.com |
